Results-based contracts—also known as value-based contracts—have the potential to lower costs for patients and the health system. Despite the promise of these innovative payment approaches, regulations instituted before innovative contracting approaches were developed can create uncertainty for biopharmaceutical companies looking to pursue these contracts and can discourage them from entering into these beneficial agreements.